A study has shown that more drugs need to be subject to PVA negotiations due to the expanded scope of use.

In other words, the current standard, which sets the expected additional claims amount in the KRW 10 billion range needs to be expanded to KRW 5 billion, and drugs with an expected increase rate of more than 100 % should also be subject to negotiations.

Such results were disclosed as part of the 'Study on the Performance and Improvement of the Scope of Use Expansion Negotiation System' that was conducted as a research service for the National Health Insurance Service (Research Institute Yonsei University, Industry-Academia Cooperation Center, Professor Euna Han).